Adverse Drug Reactions & Pharmacovigilance Basics

An adverse drug reaction (ADR) is a harmful, unintended response to a drug at a normal therapeutic dose — distinct from overdose or medication error. Pharmacovigilance is the science of detecting, assessing and preventing ADRs after drugs reach the market, because trials of a few thousand patients cannot reveal rare effects that appear when millions take the drug.

This matters because ADRs hospitalize millions yearly and some are fatal — thalidomide caused severe birth defects before systematic monitoring existed. Every ADR report a doctor files can trigger label warnings, restricted use, or withdrawal of a dangerous drug.

Key Concepts

• Type A (augmented): predictable, dose-related extensions of known action — bleeding from warfarin, hypoglycemia from insulin. Common; managed by dose reduction.
• Type B (bizarre): unpredictable, not dose-related — allergies, anaphylaxis, Stevens–Johnson syndrome. Rare but severe; stop the drug and never rechallenge.
• Other types: C (chronic — analgesic kidney damage), D (delayed — cancer years after chemotherapy), E (end-of-use withdrawal), F (failure of therapy).
• Naranjo scale: scores causality (definite, probable, possible, doubtful) with 10 yes/no questions — timing, dechallenge (improvement on stopping), rechallenge, alternative causes, known literature.
• Pharmacovigilance systems: spontaneous reporting to national centers (India's PvPI) feeds the WHO global database (VigiBase); signals trigger regulatory action.
• Key terms: side effect (any unintended effect, possibly harmless); adverse event (any bad event during treatment, not necessarily drug-caused); ADR (drug implicated).

How It Works

1. Suspect: unexpected symptom on a drug — rash after a new antibiotic.
2. Assess causality: Naranjo questions — timing, dechallenge, rechallenge, alternatives, known link.
3. Act: stop or substitute for type B; reduce dose for type A; treat the reaction.
4. Report: file with the national center — drug, dose, dates, reaction, outcome.
5. Signal detection: aggregated reports trigger investigation, label changes, warnings, or withdrawal (rofecoxib was withdrawn after cardiovascular signals).

Worked Example

A patient develops a widespread rash 5 days after starting allopurinol; it fades over 2 weeks after stopping. Simplified Naranjo: Step 1: reaction followed the drug (+2). Step 2: improved on stopping (+1). Step 3: no alternative cause found (0). Step 4: allopurinol rash is well documented (+1). Step 5: rechallenge not done (0). Step 6: total ~5–6 points = "probable" (range 5–8). Conclusion: document as drug allergy, never represcribe, and file the ADR report. Structured scoring turns a hunch into a defensible decision.

Common Misconceptions

• "Approved means completely safe." Approval means benefits outweigh known risks in thousands; rare ADRs (1 in 10,000) emerge only after millions use the drug.
• "Side effects mean stop immediately." Many type A effects fade as the body adjusts; abrupt stopping can cause withdrawal or rebound. Consult the prescriber first.
• "Reporting blames the doctor." ADRs occur with perfect prescribing — type B reactions are unpredictable. Reports carry no penalty and improve safety for all.

Real-World Applications

• Clinical practice: counseling on warning signs and documenting drug allergies prevents repeat reactions.
• Regulation: PvPI and the WHO programme convert individual reports into global safety signals and label updates.
• Withdrawals: rofecoxib's withdrawal after post-marketing heart-attack signals likely prevented thousands of deaths.
• Patient reporting: patients can report ADRs directly through national portals — consumer reports are a recognized signal source.

ADRs range from predictable dose effects to bizarre immune catastrophes, and pharmacovigilance is the world's early-warning system. Suspect, assess with structured causality, act for the patient, and report — the next report filed could be the one that saves thousands.